IP Library › Granted Patent US 12,534,717
Granted Patent B2
US 12,534,717 · App. 17/239,132 · Granted Jan 27, 2026

AAV capsid proteins for nucleic acid transfer

Inventors: Leszek Lisowski (San Mateo, CA); Mark A. Kay (Los Altos, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C12N15/1058C07K14/005C12N7/00C12N2750/14121C12N2750/14122C12N2750/14141C12N2750/14143C12N2750/14151C12N2750/14152
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,717
App. No.
17/239,132
Granted
Jan 27, 2026
Kind
B2
Abstract

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Claims (21)

1 . A recombinant viral vector, comprising: a capsid protein with an amino acid sequence comprising, relative to wildtype AAV3B, at least one amino acid substitution selected from the group consisting of (i) a conservative substitution at amino acid residues 26, 29, 105 and/or 125, (ii) a semi-conservative substitution at amino acid residue 29, and (iii) a non-conservative amino acid substitution at amino acid residue 42 and/or 67.

2 . The recombinant viral vector of claim 1 , wherein the at least one amino acid substitution comprises a glutamine substitution relative to wildtype AAV3B at position 26.

3 . The recombinant viral vector of claim 1 , wherein the at least one amino acid substitution comprises an alanine substitution relative to wildtype AAV3B at position 29.

4 . The recombinant viral vector of claim 1 , further comprising a lysine substitution relative to wildtype AAV3B at position 31.

5 . The recombinant viral vector of claim 1 , further comprising an alanine substitution relative to wildtype AAV3B at position 42.

6 . The recombinant viral vector of claim 1 , wherein the at least one amino acid substitution comprises an alanine substitution relative to wildtype AAV3B at position 67.

7 . The recombinant viral vector of claim 1 , wherein the at least one amino acid substitution comprises a lysine substitution relative to wildtype AAV3B at position 105.

8 . The recombinant viral vector of claim 1 , further comprising a proline substitution relative to wildtype AAV3B at position 735.

9 . A recombinant viral vector, comprising: a capsid protein with an amino acid sequence comprising, relative to wildtype AAV3B, one or more of a substitution at amino acid residues 26, 29, 31, 42, 67, 105 and/or 735.

10 . The recombinant viral vector of claim 9 , wherein the amino acid sequence comprises a glutamine substitution relative to wildtype AAV3B at residue 26.

11 . The recombinant viral vector of claim 9 , wherein the amino acid sequence comprises an alanine substitution relative to wildtype AAV3B at residue 29.

12 . The recombinant viral vector of claim 9 , wherein the amino acid sequence comprises a lysine substitution relative to wildtype AAV3B at residue 31.

13 . The recombinant viral vector of claim 9 , wherein the amino acid sequence comprises an alanine substitution relative to wildtype AAV3B at residue 42.

14 . The recombinant viral vector of claim 9 , wherein the amino acid sequence comprises an alanine substitution relative to wildtype AAV3B at residue 67.

15 . The recombinant viral vector of claim 9 , wherein the amino acid sequence comprises a lysine substitution relative to wildtype AAV3B at residue 105.

16 . The recombinant viral vector of claim 9 , wherein the amino acid sequence comprises a proline substitution relative to wildtype AAV3B at residue 735.

17 . A method for transduction of a gene of interest, comprising, providing a recombinant viral vector having a capsid protein, where the capsid protein comprises mutations at positions 26, 29, 31, 42, 67, 105 and 735, relative to wildtype AAV3B.

18 . The recombinant viral vector of claim 1 , further comprising an insertion of Val and Glu between positions 680 and 681 of wildtype AAV3B.

19 . The recombinant viral vector of claim 1 , further comprising an alanine substitution at position 29, a lysine substitution at position 31, and an alanine substitution at position 67.

20 . The recombinant viral vector of claim 19 , wherein the at least one amino acid substitution comprises a conservative substitution at amino acid residue 125.

21 . The recombinant viral vector of claim 19 , further comprising an insertion of Val and Glu between positions 680 and 681 of wildtype AAV3B.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2021
From: LISOWSKI, LESZEK; KAY, MARK A.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 056737/0764 →
Continuity (6)
Continuation 15829639 · Dec 1, 2017
Division 14853552 · Sep 14, 2015
Division 13594773 · Aug 24, 2012
Provisional Application 61545488 · Oct 10, 2011
Provisional Application 61526688 · Aug 24, 2011
Related Publication 20210355481A1 · Nov 18, 2021
References Cited (32)
US 7749492B2 · Bartlett et al. · 2010 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 9169299B2 · Lisowski et al. · 2015 [cited by applicant]
US 9856469B2 · Lisowski et al. · 2018 [cited by applicant]
US 11015189B2 · Lisowski et al. · 2021 [cited by applicant]
US 20030138772A1 · Gao et al. · 2003 [cited by applicant]
US 20050287122A1 · Bartlett et al. · 2005 [cited by applicant]
US 20100047174A1 · Kay et al. · 2010 [cited by applicant]
US 20130059732A1 · Lisowski et al. · 2013 [cited by applicant]
US 20150376607A1 · Lisowski et al. · 2015 [cited by applicant]
US 20180258420A1 · Lisowski et al. · 2018 [cited by applicant]
EP 2298926A1 · 2011 [cited by applicant]
WO WO2006119432A2 · 2006 [cited by applicant]
WO WO2009137006A2 · 2009 [cited by applicant]
WO WO2013029030A1 · 2013 [cited by applicant]
Azuma et al., “Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/112rg-/-mice”, Nature Biotechnol., vol. 25, No. 8, pp. 903-910 (Epub 2007). [cited by applicant]
Crameri et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, vol. 391, pp. 288-291 (1998). [cited by applicant]
Diprimio et al., “Surface loop dynamics in adeno-associated virus capsid assembly”, J. Virol., vol. 82, pp. 5178-5189 (2008). [cited by applicant]
Gao et al., “Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy”, Proceedings of the National Acadamy of Sciences, vol. 99, No. 18, pp. 11854-11859 (2002). [cited by applicant]
Gao et al., “Clades of Adeno-associated viruses are widely disseminated in human tissues”, J. Virol., vol. 78, No. 12, pp. 6381-6388 (2004). [cited by applicant]
Genbank Accession No. AF513852.1, publicly available Sep. 2002. [cited by applicant]
GenBank Accession No. YP_077180.1, publicly available Sep. 2004. [cited by applicant]
Grimm et al., “Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy”, Blood, vol. 102, No. 7, pp. 2412-2419 (2003). [cited by applicant]
International Search Report from PCT Patent Application No. PCT/US2012/052400, search report mailed on Jan. 18, 2013, application now published as International Publication No. WO2013/029030 on Feb. 28, 2013. [cited by applicant]
Kern et al., “Identification of a heparin-binding motif on adeno-associated virus type 2 capsids”, J. Virol., vol. 77, No. 20, pp. 11072-11081 (2003). [cited by applicant]
Logan and Shenk, “Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection”, Proc. Natl. Acad. Sci. USA, vol. 81, No. 12, pp. 3655-3659 (1984). [cited by applicant]
Mackett et al., “Vaccinia virus: a selectable eukaryotic cloning and expression vector”, Proc. Natl. Acad. Sci. USA, vol. 79, No. 23, pp. 7415-7419 (1982). [cited by applicant]
Mackett et al., “General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes”, J. Virol., vol. 49, No. 3, pp. 857-864 (1984). [cited by applicant]
Manno et al., “Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response”, Nature Medicine, vol. 12, No. 3, pp. 342-347 (2006). [cited by applicant]
Panicali et al., “Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus”, Proc. Natl. Acad. Sci. USA, vol. 79, No. 16, … [cited by applicant]
Rutledge et al., “Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2”, J. Virol, vol. 72, No. 1, pp. 309-319 (1998). [cited by applicant]
Summerford et al., “Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions”, J. Virol., vol. 72, No. 2, pp. 1438-1445 (1998). [cited by applicant]